Moderna is downsizing its workforce by 10% globally to bring headcount to under 5,000 in “a difficult moment for the company, ...

Employed biopharma professionals are highly likely to look for new jobs in the next 12 months, although not quite as likely ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical ...